(Q40957762)

25 September 2017

1 reference

title

The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review (English)

1 reference

25 September 2017

1 reference

Saracco G

1

1 reference

PubMed ID

8580412

25 September 2017

Rizzetto M

series ordinal

2

1 reference

25 September 2017

1 November 1995

1 reference

Journal of Gastroenterology and Hepatology

25 September 2017

1 reference

25 September 2017

10

1 reference

25 September 2017

6

1 reference

25 September 2017

668-673

1 reference

Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience

25 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Detection of hepatitis C virus RNA in serum and peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Reliability of polymerase chain reaction for detection of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Hepatitis C virus replication and antibodies to structural and nonstructural viral proteins in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Quantitative analysis of antibodies to hepatitis C virus during interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Prediction of response to interferon treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Hepatitis C virus serotype II responds more favorably to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Hepatitis C virus after interferon treatment has the variation in the hypervariable region of envelope 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response,

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.1995.TB01369.X

10.1111/J.1440-1746.1995.TB01369.X

21 January 2018

Identifiers

DOI

1 reference

release_6ttpcjwsgjhlzgryjooj3ornvm

25 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6ttpcjwsgjhlzgryjooj3ornvm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

8580412

1 reference

PubMed ID

8580412